Tan Kevin 4

What Happened

• Kevin Tan, CFO & Treasurer of Solid Biosciences (SLDB), sold 26,837 shares on Feb 2, 2026 at a weighted-average price of $6.44, generating approximately $172,747. The sale was a sell-to-cover to satisfy tax withholding following the vesting/conversion of performance units.
• Related entries show conversions/exercises of derivatives on Jan 29 (56,646 shares) and Jan 31 (33,075 shares), and grant/award entries on Jan 29 for 187,000 and 93,500 derivative units (PSUs/RSUs) that convert one-for-one to common shares. The PSU vesting was triggered by a board-certified performance milestone on Jan 29, 2026 (25% of the PSU target vested).

Key Details

• Transaction dates and prices: Jan 29, 2026 (conversion/exercise entries), Jan 31, 2026 (conversion/exercise entries), Feb 2, 2026 sale at weighted avg $6.44 (individual sale prices ranged $6.295–$6.58).
• Shares sold: 26,837; proceeds ≈ $172,747. Conversions/exercises reported: 56,646 and 33,075 shares. Awards reported on Jan 29: 187,000 and 93,500 PSUs/RSUs.
• Shares owned after the transactions: not specified in the provided filing excerpt.
• Notable footnotes: the Feb 2 sale was an automatic sell-to-cover for withholding taxes (non-discretionary) per Mr. Tan’s durable instruction; PSUs convert 1:1 to common stock and 25% vested upon meeting a specified performance milestone on Jan 29, 2026; sale price reported is a weighted average and covered multiple execution prices.
• Filing timing: Form 4 filed Feb 2, 2026 reporting transactions through Jan 29, 2026; the filing is not marked as late.

Context

• These entries reflect awards vesting and derivative conversions, not an open-market, discretionary sell motivated by trade timing. The sale was to cover taxes on vested PSUs (a routine, non-discretionary sell-to-cover). For retail investors, awards and vesting are informative about compensation and dilution; purchases would be a stronger bullish signal.